VERAXA Biotech Appoints Veteran CFO Raju Willener to Drive Capital Strategy

VERAXA Biotech (NASDAQ: VRXA), a pioneer in next-generation antibody-based cancer therapies, has announced the appointment of Raju Willener as its new Chief Financial Officer, effective immediately. Willener, who brings over three decades of international financial leadership, will report directly to CEO and Co-Founder Christoph Antz, Ph.D. His extensive background in global capital markets, investment banking, and corporate finance is expected to bolster the company's capital strategy and support the advancement of its proprietary BiTAC(R) technology platform and oncology pipeline.

Before joining VERAXA, Willener served as CFO at Exentis Group AG, where he was instrumental in leading M&A initiatives and financial strategy. Earlier in his career, he held senior roles overseeing corporate finance, investor relations, and investment portfolios exceeding CHF 30 billion in assets under management. This wealth of experience will be invaluable as VERAXA continues to develop its bispecific T cell engagers and antibody-drug conjugates, aimed at transforming cancer treatment.

VERAXA's innovative approach is rooted in scientific breakthroughs from the European Molecular Biology Laboratory (EMBL), positioning it at the forefront of oncology research. The company's newsroom at http://nnw.fm/VRXA provides the latest updates. NetworkNewsWire ("NNW"), a key distributor of this announcement, is part of the Dynamic Brand Portfolio @ IBN, which offers comprehensive corporate communications solutions. The appointment of a seasoned financial executive like Willener signals VERAXA's readiness to accelerate its growth and potentially attract strategic partnerships, making this a significant development for investors and the biotech industry.